Short Interest in Arcellx, Inc. (NASDAQ:ACLX) Expands By 25.8%

Arcellx, Inc. (NASDAQ:ACLX) was the recipient of a significant growth in short interest in December. As of December 15th, there was short interest totaling 8,112,318 shares, a growth of 25.8% from the November 30th total of 6,449,275 shares. Approximately 15.3% of the shares of the stock are sold short. Based on an average daily trading volume, of 1,529,016 shares, the short-interest ratio is presently 5.3 days. Based on an average daily trading volume, of 1,529,016 shares, the short-interest ratio is presently 5.3 days. Approximately 15.3% of the shares of the stock are sold short.

Insider Transactions at Arcellx

In related news, insider Christopher Heery sold 340 shares of Arcellx stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $90.00, for a total value of $30,600.00. Following the transaction, the insider owned 284 shares of the company’s stock, valued at approximately $25,560. This trade represents a 54.49% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 8.35% of the company’s stock.

Institutional Trading of Arcellx

Several large investors have recently made changes to their positions in the stock. RA Capital Management L.P. grew its stake in shares of Arcellx by 8.9% in the first quarter. RA Capital Management L.P. now owns 3,036,527 shares of the company’s stock worth $199,196,000 after acquiring an additional 249,200 shares during the last quarter. Vestal Point Capital LP grew its position in Arcellx by 15.2% in the 2nd quarter. Vestal Point Capital LP now owns 2,750,000 shares of the company’s stock worth $181,088,000 after purchasing an additional 362,280 shares during the last quarter. JPMorgan Chase & Co. grew its position in Arcellx by 42.9% in the 2nd quarter. JPMorgan Chase & Co. now owns 976,968 shares of the company’s stock worth $64,333,000 after purchasing an additional 293,387 shares during the last quarter. Bamco Inc. NY increased its holdings in shares of Arcellx by 6.2% during the 3rd quarter. Bamco Inc. NY now owns 550,236 shares of the company’s stock worth $45,174,000 after purchasing an additional 32,227 shares during the period. Finally, Decheng Capital LLC raised its position in shares of Arcellx by 995.2% during the second quarter. Decheng Capital LLC now owns 547,609 shares of the company’s stock valued at $36,060,000 after buying an additional 497,609 shares during the last quarter. Institutional investors own 96.03% of the company’s stock.

Arcellx Stock Down 2.3%

ACLX stock opened at $63.60 on Wednesday. The firm has a 50 day moving average of $77.65 and a two-hundred day moving average of $74.84. Arcellx has a 12 month low of $47.86 and a 12 month high of $94.07. The company has a market capitalization of $3.68 billion, a price-to-earnings ratio of -16.18 and a beta of 0.34.

Arcellx (NASDAQ:ACLX) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.96) by ($0.03). The business had revenue of $4.95 million during the quarter, compared to analyst estimates of $11.24 million. Arcellx had a negative net margin of 607.01% and a negative return on equity of 51.13%. On average, research analysts expect that Arcellx will post -1.58 EPS for the current fiscal year.

Analysts Set New Price Targets

ACLX has been the topic of several research analyst reports. Guggenheim reaffirmed a “buy” rating on shares of Arcellx in a research note on Monday, November 24th. Wolfe Research started coverage on shares of Arcellx in a report on Tuesday, November 18th. They set a “peer perform” rating for the company. Stifel Nicolaus set a $129.00 price objective on shares of Arcellx and gave the company a “buy” rating in a research note on Thursday, October 16th. Wells Fargo & Company started coverage on shares of Arcellx in a research report on Monday, December 22nd. They issued an “overweight” rating and a $100.00 target price for the company. Finally, Citigroup restated a “buy” rating on shares of Arcellx in a report on Monday, November 24th. Eight research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Arcellx presently has a consensus rating of “Moderate Buy” and an average target price of $113.75.

About Arcellx

Arcellx, Inc (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company’s proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.

The company’s pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development.